Four-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Hepatitis C–Viremic Donors to Hepatitis C–Negative Recipients: An Open-Label Nonrandomized Study

Case series (n=10) found that in all recipients of hepatitis C virus donor positive kidneys, 4 weeks of glecaprevir, 300 mg, and pibrentasvir, 120 mg prophylaxis prevented hepatitis C virus infection in the recipient without treatment-related adverse events.


Annals of Internal Medicine